Health & Bio

Lilly ships Foundayo oral obesity drug; Novo pill competition heats up

Lilly launches three months after Novo oral GLP-1. Foundayo 17% weight loss trails Wegovy pill. Telehealth demand surges.

Primary sources · 2
CNBCDrug Discovery Trends
Related storylines
#2026-W14-04 · GLP-1 market enters triple inflection point: oral agents, insurance cliff, and end of 503B compounding
← View the full 2026-05-16 (Saturday) issue
What you're reading now arrives in your inbox daily at 21:00 UTC.

Get today's brief every day at 21:00 UTC

7 must-reads · 17 fields · tracked storylines delivered to your inbox daily. Pick only the fields you want; unsubscribe anytime.

Past issues →